GLAXF - GlaxoSmithKline plc

Other OTC - Other OTC Delayed price. Currency in USD
20.71
+0.48 (+2.37%)
At close: 9:51AM EDT
Stock chart is not supported by your current browser
Previous close20.23
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Volume0
Avg. volume5,854
Market cap102.317B
Beta0.87
PE ratio (TTM)47.39
EPS (TTM)0.44
Earnings dateN/A
Forward dividend & yield1.11 (5.50%)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
  • Business Wire14 hours ago

    Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients With COPD

    LONDON & BRISBANE, Calif.--(BUSINESSWIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded ...

  • Business Wire14 hours ago

    Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients With COPD

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means Trelegy Ellipta can now be used by US physicians to treat a broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation or who have experienced an acute worsening of respiratory symptoms. The new indication is for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.

  • What's in the Cards for Glaxo (GSK) This Earnings Season?
    Zacks5 days ago

    What's in the Cards for Glaxo (GSK) This Earnings Season?

    Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.

  • Better Buy: GlaxoSmithKline plc (GSK) vs. Eli Lilly (LLY)
    Motley Fool5 days ago

    Better Buy: GlaxoSmithKline plc (GSK) vs. Eli Lilly (LLY)

    Which stock wins in a head-to-head matchup of these two big pharma companies?

  • Sanofi to Divest European Generic Unit, Streamline Business
    Zacks6 days ago

    Sanofi to Divest European Generic Unit, Streamline Business

    Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.

  • Reuters6 days ago

    Experts query case for GlaxoSmithKline's new 3-in-1 lung drug

    Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline (GSK.L), which the company hopes will help it keep its lead in respiratory medicine despite rising competition. Trelegy Ellipta was licensed for use last year and full results from a positive clinical trial were published on Wednesday in the New England Journal of Medicine (NEJM). Trelegy is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca (AZN.L) and Novartis (NOVN.S), and it showed benefits over other treatments in the study.

  • Business Wire6 days ago

    Landmark IMPACT Study Published in NEJM Shows Significant Benefits of Trelegy Ellipta for Patients with COPD

    A significant reduction in the risk of on-treatment all-cause mortality was observed for both inhaled corticosteroid containing arms compared to Anoro. Dave Allen, Head, Respiratory Therapy Area R&D, GSK, said, “Reducing exacerbations to keep patients out of hospital is a key goal of COPD management alongside improving lung function and quality of life. The IMPACT study shows how Trelegy Ellipta can help patients with a history of exacerbation achieve these goals.

  • Reuters - UK Focus6 days ago

    Experts query case for GlaxoSmithKline's new 3-in-1 lung drug

    Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline (Other OTC: GLAXF - news) , which the company hopes will help it keep its lead in respiratory medicine despite rising competition. Trelegy Ellipta was licensed for use last year and full results from a positive clinical trial were published on Wednesday in the New England Journal of Medicine (NEJM). Trelegy is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca (NYSE: AZN - news) and Novartis (IOB: 0QLR.IL - news) , and it showed benefits over other treatments in the study.

  • GSK flags pharma M&A ambitions by poaching Roche deal-maker
    Reuters7 days ago

    GSK flags pharma M&A ambitions by poaching Roche deal-maker

    GlaxoSmithKline (GSK.L) signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's (ROG.S) Genentech unit to lead a worldwide search for promising experimental products. Barron is also a veteran of Genentech, famous for its biotech cancer medicines.

  • Reuters - UK Focus7 days ago

    GSK flags pharma M&A ambitions by poaching Roche deal-maker

    GlaxoSmithKline (Amsterdam: GO8.AS - news) signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's Genentech unit to lead a worldwide search for promising experimental products.

  • Reuters - UK Focus7 days ago

    GSK grabs Roche cancer expert to lead pharma pipeline deals

    GlaxoSmithKline said on Wednesday it had hired Kevin Sin from Roche's Genentech unit to head worldwide business development for pharmaceuticals research and development. Sin, who will join GSK in San Francisco ...

  • Glaxo, Novartis Join $4 Billion Gates-Led Push to Fight Malaria
    Bloomberg7 days ago

    Glaxo, Novartis Join $4 Billion Gates-Led Push to Fight Malaria

    GlaxoSmithKline Plc and Novartis AG will contribute research funds to an almost $4 billion global effort to combat malaria as drug-resistant strains of the disease threaten to undo years of progress.

  • Mylan Denies Report It's Interested In Buying Merck KGaA's Consumer Biz
    Investor's Business Daily11 days ago

    Mylan Denies Report It's Interested In Buying Merck KGaA's Consumer Biz

    Mylan denied reports Friday that it's interested in buying Merck KGaA's consumer health care business, after Reckitt Benckiser and Nestle reportedly dumped their bids.

  • Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III
    Zacks11 days ago

    Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III

    Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program.

  • Glaxo to Sell Rare Disease Gene Therapies to Private Biotech
    Zacks12 days ago

    Glaxo to Sell Rare Disease Gene Therapies to Private Biotech

    Glaxo (GSK) will divest its rare disease gene therapy drugs to private biotech Orchard Therapeutics in exchange for a 19.9% stake in the company as well as a seat on its board.

  • Reuters13 days ago

    GSK slims portfolio with sale of rare disease gene therapy drugs

    GlaxoSmithKline (GSK.L) is divesting its rare disease gene therapy drugs to private biotech company Orchard Therapeutics as Chief Executive Emma Walmsley makes good on her promise to prune the drugmaker's pharmaceuticals portfolio. Financially, the transaction will not move the dial for Britain's biggest drugmaker, but it offers a sign that Walmsley is making progress in reshaping the company since her arrival a year ago.

  • Reuters - UK Focus13 days ago

    GSK slims portfolio with sale of rare disease gene therapy drugs

    GlaxoSmithKline (Other OTC: GLAXF - news) is divesting its rare disease gene therapy drugs to private biotech company Orchard Therapeutics as Chief Executive Emma Walmsley makes good on her promise to prune the drugmaker's pharmaceuticals portfolio. Financially, the transaction will not move the dial for Britain's biggest drugmaker, but it offers a sign that Walmsley is making progress in reshaping the company since her arrival a year ago.

  • Zacks Market Edge Highlights: Exxon, Diageo, GlaxoSmithKline, Micron and AMN
    Zacks13 days ago

    Zacks Market Edge Highlights: Exxon, Diageo, GlaxoSmithKline, Micron and AMN

    Zacks Market Edge Highlights: Exxon, Diageo, GlaxoSmithKline, Micron and AMN

  • MarketWatch13 days ago

    U.K. stocks waver as traders remain wary over Syria conflict

    U.K. stocks struggle for direction on Thursday, as investors remain nervous over the potential for a military conflict in Syria and digested the latest Federal Reserve minutes.

  • Reuters13 days ago

    UK gene therapy firm Orchard plans stock offer after GSK deal

    Britain's Orchard Therapeutics, which has already raised more than $140 million (98.54 million pounds) to fund its work in gene therapy, plans another private sale of shares following its acquisition of a portfolio of GlaxoSmithKline (GSK.L) rare disease medicines. Chief Executive Mark Rothera also told Reuters that an initial public offering (IPO) was an option beyond this next private financing move. Gene therapy is a hot area for drug research - highlighted by Novartis's (NOVN.S) $8.7 billion acquisition of AveXis (AVXS.O) this week - but the rare disease products sold to Orchard are too niche for GSK as it refocuses its R&D efforts.

  • Reuters - UK Focus13 days ago

    GSK divests rare disease gene therapy drugs to Orchard Therapeutics

    GlaxoSmithKline said on Thursday is was transferring its rare disease gene therapy drugs to Orchard Therapeutics as Chief Executive Emma Walmsley makes good on her promise to prune the drugmaker's pharmaceuticals ...

  • Pfizer's Kidney Cancer Drug Misses Endpoint in Phase III
    Zacks14 days ago

    Pfizer's Kidney Cancer Drug Misses Endpoint in Phase III

    Pfizer's (PFE) kidney cancer drug Inlyta (axitinib) fails to demonstrate a clear improvement in the primary endpoint of extending disease-free survival (DFS) in a late-stage study.

  • Reuters15 days ago

    New GSK shingles vaccine off to strong start in key U.S. market

    GlaxoSmithKline's new shingles vaccine - a priority product as the company strives to improve its drugs line-up - has won more than 90 percent U.S. market share just five months after its launch, prescription-tracking data show. The healthy take-up comes at the expense of Merck & Co's older and less effective product Zostavax, which has seen a slump in demand. The U.S. Centers for Disease Control and Prevention has recommended Shingrix over Zostavax in adults 50 years and older, spurring demand for the GSK vaccine.

  • Reuters - UK Focus15 days ago

    New GSK shingles vaccine off to strong start in key U.S. market

    GlaxoSmithKline (Other OTC: GLAXF - news) 's new shingles vaccine - a priority product as the company strives to improve its drugs line-up - has won more than 90 percent U.S. market share just five months after its launch, prescription-tracking data show. The healthy take-up comes at the expense of Merck & Co (Swiss: MRK-USD.SW - news) 's older and less effective product Zostavax, which has seen a slump in demand. The U.S. Centers for Disease Control and Prevention has recommended https://www.cdc.gov/vaccines/vpd/shingles/hcp/shingrix/recommendations.html Shingrix over Zostavax in adults 50 years and older, spurring demand for the GSK vaccine.

  • Novartis bets big on gene therapy with $8.7 billion AveXis deal
    Reuters16 days ago

    Novartis bets big on gene therapy with $8.7 billion AveXis deal

    Swiss drugmaker Novartis (NOVN.S) is moving further into gene therapy by buying AveXis (AVXS.O) for $8.7 billion (£6.17 billion) , adding a rare-disease treatment that could reap billions in sales. The $218-per-share cash deal announced on Monday represents a 72 percent premium to AveXis's 30-day volume-weighted average stock price. Novartis Chief Executive Vas Narasimhan, who took over on Feb. 1, is flush with cash, having just agreed to sell his company's stake in a consumer healthcare joint venture to GlaxoSmithKline (GSK.L) for $13 billion.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes